Journal
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume 40, Issue -, Pages 31-36Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BST20110608
Keywords
autotaxin; cancer; drug discovery; lysophosphatidic acid (LPA); 4-pentadecylbenzylphosphonic acid (4-PBA); therapy
Categories
Funding
- National Institutes of Health [CA092160]
- Grants-in-Aid for Scientific Research [22790203] Funding Source: KAKEN
Ask authors/readers for more resources
LPA (lysophosphatidic acid, 1-acyl-2-hydroxy-sn-glycero-3-phosphate), is a growth factor-like lipid mediator that regulates many cellular functions, many of which are unique to malignantly transformed cells. The simple chemical structure of LPA and its profound effects in cancer cells has attracted the attention of the cancer therapeutics field and drives the development of therapeutics based on the LPA scaffold. In biological fluids, LPA is generated by ATX (autotaxin), a lysophospholipase D that cleaves the choline/serine headgroup from lysophosphatidylcholine and lysophosphatidylserine to generate IPA. In the present article, we review some of the key findings that make the ATX-LPA signalling axis an emerging target for cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available